February 18, 2026 · Form 4 insider transaction
Kulkarni Samarth bought 13,250 shares of CRISPR Therapeutics AG, a transaction worth N/A. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 2 days after the transaction.
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.; Reflects 85,622 shares previously transferred from the Kulkarni 2023 GRAT to the Reporting Person.